The AstraZeneca vaccine is 79% effective in preventing symptomatic infections

According to a large-scale trial in the United States, the Coronary Disease Vaccine jointly developed by Oxford University and AstraZeneca is 79% effective in preventing symptomatic coronary disease infection and 100% in preventing severe illness and hospitalization.

Reuters and Bloomberg reported that Oxford University said on Monday (22nd) that more than 32,000 volunteers participated in the third phase of clinical trials in the United States, Chile, and Peru, and the ages of the participants covered all age groups.

Oxford University said that the test results showed that the AstraZeneca vaccine was safe and highly effective, and no safety concerns were found.

However, a poll published on the same day showed that in the past few weeks, there have been many cases of problems such as blood clots caused by the AstraZeneca crown disease vaccine, which has led to a sharp decline in European countries’ trust in this vaccine.

According to a survey conducted by the British polling agency YouGov, most people in the largest EU member states, including Germany, France, Spain and Italy, now believe that AstraZeneca vaccines are unsafe.

However, there is generally a positive view of the AstraZeneca vaccine in the United Kingdom. Two-thirds of the respondents think it is safe, and only 9% think it is unsafe.

The European Medicines Agency announced on March 18 the results of the review of the AstraZeneca vaccine, stating that the AstraZeneca vaccine is safe and effective, saying that the benefits of vaccination outweigh the potential risks of vaccination. The World Health Organization (WHO) and the British Drug Administration also Publish the same conclusion.